{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:38:34Z","timestamp":1793234314676,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s15010-019-01291-9","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T03:36:15Z","timestamp":1551843375000},"page":"363-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["AmpC \u03b2-lactamase-producing Enterobacterales: what a clinician should know"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8711-8305","authenticated-orcid":false,"given":"Simone","family":"Meini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Sozio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Rossolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"1291_CR1","doi-asserted-by":"publisher","first-page":"30583","DOI":"10.2807\/1560-7917.ES.2017.22.31.30583","volume":"22","author":"T Giani","year":"2017","unstructured":"Giani T, Antonelli A, Caltagirone M, Mauri C, Nicchi J, Arena F, et al. The AMCLI-CoSA survey participants. Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients. Euro Surveill. 2017;22:30583.","journal-title":"Euro Surveill"},{"key":"1291_CR2","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1056\/NEJMra041359","volume":"352","author":"GA Jacoby","year":"2005","unstructured":"Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med. 2005;352:380\u201391.","journal-title":"N Engl J Med"},{"key":"1291_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.drup.2004.02.003","volume":"7","author":"BG Hall","year":"2004","unstructured":"Hall BG, Barlow M. Evolution of the serine beta-lactamases: past, present and future. Drug Resist Updat. 2004;7:111\u201323.","journal-title":"Drug Resist Updat"},{"key":"1291_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/146837a0","volume":"146","author":"EP Abraham","year":"1940","unstructured":"Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature. 1940;146:837.","journal-title":"Nature"},{"key":"1291_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1128\/CMR.00036-08","volume":"22","author":"GA Jacoby","year":"2009","unstructured":"Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161\u201382.","journal-title":"Clin Microbiol Rev"},{"key":"1291_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/AAC.01009-09","volume":"54","author":"K Bush","year":"2010","unstructured":"Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969\u201376.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1186\/s12879-014-0647-4","volume":"14","author":"VP Chaubey","year":"2014","unstructured":"Chaubey VP, Pitout JD, Dalton B, Gregson DB, Ross T, Laupland KB. Clinical and microbiological characteristics of bloodstream infections due to AmpC \u03b2-lactamase producing Enterobacteriaceae: an active surveillance cohort in a large centralized Canadian region. BMC Infect Dis. 2014;14:647.","journal-title":"BMC Infect Dis"},{"key":"1291_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijantimicag.2012.10.022","volume":"41","author":"M Hilty","year":"2013","unstructured":"Hilty M, Sendi P, Seiffert SN, Droz S, Perreten V, Hujer AM, et al. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? Int J Antimicrob Agents. 2013;41:236\u201349.","journal-title":"Int J Antimicrob Agents"},{"key":"1291_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40262-017-0584-7","volume":"57","author":"K Alexandre","year":"2018","unstructured":"Alexandre K, Fantin B. Pharmacokinetics and Pharmacodynamics of Temocillin. Clin Pharmacokinet. 2018;57:287\u201396.","journal-title":"Clin Pharmacokinet"},{"key":"1291_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1574-6968.2008.01126.x","volume":"282","author":"H Mammeri","year":"2008","unstructured":"Mammeri H, Nordmann P, Berkani A, Eb F. Contribution of extended-spectrum AmpC (ESAC) beta-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol Lett. 2008;282:238\u201340.","journal-title":"FEMS Microbiol Lett"},{"key":"1291_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1517\/14656566.2016.1154538","volume":"17","author":"RG D\u2019Angelo","year":"2016","unstructured":"D\u2019Angelo RG, Johnson JK, Bork JT, Heil EL. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. Expert Opin Pharmacother. 2016;17:953\u201367.","journal-title":"Expert Opin Pharmacother"},{"key":"1291_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.7326\/0003-4819-115-8-585","volume":"115","author":"JW Chow","year":"1991","unstructured":"Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115:585\u201390.","journal-title":"Ann Intern Med"},{"key":"1291_CR13","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1128\/AAC.01083-07","volume":"52","author":"SH Choi","year":"2008","unstructured":"Choi SH, Lee JE, Park SJ, Choi SH, Lee SO, Jeong JY, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother. 2008;52:995\u20131000.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR14","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1128\/JCM.00091-11","volume":"49","author":"S Peter-Getzlaff","year":"2011","unstructured":"Peter-Getzlaff S, Polsfuss S, Poledica M, Hombach M, Giger J, B\u00f6ttger EC, et al. Detection of AmpC beta-lactamase in Escherichia coli: comparison of three phenotypic confirmation assays and genetic analysis. J Clin Microbiol. 2011;49:2924\u201332.","journal-title":"J Clin Microbiol"},{"key":"1291_CR15","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s10096-016-2752-3","volume":"35","author":"V Pascual","year":"2016","unstructured":"Pascual V, Alonso N, Sim\u00f3 M, Ortiz G, Garcia MC, Xercavins M, et al. Bloodstream infections caused by Escherichia coli producing AmpC \u03b2-lactamases: epidemiology and clinical features. Eur J Clin Microbiol Infect Dis. 2016;35:1997\u20132003.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1291_CR16","doi-asserted-by":"publisher","first-page":"e0204864","DOI":"10.1371\/journal.pone.0204864","volume":"13","author":"E Drijver den","year":"2018","unstructured":"den Drijver E, Verweij JJ, Verhulst C, Oome S, Soer J, Willemsen I, et al. Decline in AmpC \u03b2-lactamase-producing Escherichia coli in a Dutch teaching hospital (2013\u20132016). PLoS One. 2018;13:e0204864.","journal-title":"PLoS One"},{"key":"1291_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1469-0691.2011.03703.x","volume":"19","author":"R Leclercq","year":"2013","unstructured":"Leclercq R, Cant\u00f3n R, Brown DF, Giske CG, Heisig P, MacGowan AP, et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect. 2013;19:141\u201360.","journal-title":"Clin Microbiol Infect"},{"key":"1291_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ijantimicag.2012.06.004","volume":"40","author":"PN Harris","year":"2012","unstructured":"Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC \u03b2-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012;40:297\u2013305.","journal-title":"Int J Antimicrob Agents"},{"key":"1291_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/BF01650718","volume":"17","author":"A Bauernfeind","year":"1989","unstructured":"Bauernfeind A, Chong Y, Schweighart S. Extended broad spectrum beta-lactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection. 1989;17:316\u201321.","journal-title":"Infection"},{"key":"1291_CR20","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance. Version 2.01 July (2017). \n                    http:\/\/www.eucast.org\n                    \n                  ."},{"key":"1291_CR21","first-page":"50","volume":"128","author":"D Drinkovic","year":"2015","unstructured":"Drinkovic D, Morris AJ, Dyet K, Bakker S, Heffernan H. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials. N Z Med J. 2015;128:50\u20139.","journal-title":"N Z Med J"},{"key":"1291_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/jac\/dkx466","volume":"73","author":"PNA Harris","year":"2017","unstructured":"Harris PNA, Ben Zakour NL, Roberts LW, Wailan AM, Zowawi HM, Tambyah PA, et al. MERINO Trial investigators. Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27. J Antimicrob Chemother. 2018;73:634\u201342.","journal-title":"J Antimicrob Chemother"},{"key":"1291_CR23","doi-asserted-by":"publisher","first-page":"e0120688","DOI":"10.1371\/journal.pone.0120688","volume":"10","author":"A Conen","year":"2015","unstructured":"Conen A, Frei R, Adler H, Dangel M, Fux CA, Widmer AF. Microbiological screening is necessary to distinguish carriers of plasmid-mediated AmpC beta-lactamase-producing Enterobacteriaceae and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae because of clinical similarity. PLoS One. 2015;10:e0120688.","journal-title":"PLoS One"},{"key":"1291_CR24","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1128\/JCM.01982-13","volume":"51","author":"F Arena","year":"2013","unstructured":"Arena F, Giani T, Becucci E, Conte V, Zanelli G, D\u2019Andrea MM, et al. Large oligoclonal outbreak due to Klebsiella pneumoniae ST14 and ST26 producing the FOX-7 AmpC \u03b2-lactamase in a neonatal intensive care unit. J Clin Microbiol. 2013;51:4067\u201372.","journal-title":"J Clin Microbiol"},{"key":"1291_CR25","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1128\/AAC.50.2.618-624.2006","volume":"50","author":"MM D\u2019Andrea","year":"2006","unstructured":"D\u2019Andrea MM, Nucleo E, Luzzaro F, Giani T, Migliavacca R, Vailati F, et al. CMY-16, a novel acquired AmpC-type beta-lactamase of the CMY\/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy. Antimicrob Agents Chemother. 2006;50:618\u201324.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijantimicag.2008.09.007","volume":"33","author":"F Luzzaro","year":"2009","unstructured":"Luzzaro F, Brigante G, D\u2019Andrea MM, Pini B, Giani T, Mantengoli E, et al. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int J Antimicrob Agents. 2009;33:328\u201333.","journal-title":"Int J Antimicrob Agents"},{"key":"1291_CR27","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1128\/AAC.45.9.2628-2630.2001","volume":"45","author":"KS Kaye","year":"2001","unstructured":"Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother. 2001;45:2628\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR28","doi-asserted-by":"publisher","first-page":"e00079-17","DOI":"10.1128\/CMR.00079-17","volume":"31","author":"J Rodr\u00edguez-Ba\u00f1o","year":"2018","unstructured":"Rodr\u00edguez-Ba\u00f1o J, Guti\u00e9rrez-Guti\u00e9rrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31:e00079-17.","journal-title":"Clin Microbiol Rev"},{"key":"1291_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/cid\/cit395","volume":"57","author":"PD Tamma","year":"2013","unstructured":"Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, et al. The use of cefepime for treating AmpC \u03b2-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57:781\u20138.","journal-title":"Clin Infect Dis"},{"key":"1291_CR30","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/cid\/ciu182","volume":"58","author":"MJ Siedner","year":"2014","unstructured":"Siedner MJ, Galar A, Guzm\u00e1n-Suarez BB, Kubiak DW, Baghdady N, Ferraro MJ, et al. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis. 2014;58:1554\u201363.","journal-title":"Clin Infect Dis"},{"key":"1291_CR31","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1128\/AAC.01477-15","volume":"59","author":"NY Lee","year":"2015","unstructured":"Lee NY, Lee CC, Li CW, Li MC, Chen PL, Chang CM, Ko WC. Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates. Antimicrob Agents Chemother. 2015;59:7558\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3109\/00365548.2014.954262","volume":"46","author":"LM Blanchette","year":"2014","unstructured":"Blanchette LM, Kuti JL, Nicolau DP, Nailor MD. Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae. Scand J Infect Dis. 2014;46:803\u20138.","journal-title":"Scand J Infect Dis"},{"key":"1291_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/jac\/dkv346","volume":"71","author":"PN Harris","year":"2016","unstructured":"Harris PN, Wei JY, Shen AW, Abdile AA, Paynter S, Huxley RR, et al. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother. 2016;71:296\u2013306.","journal-title":"J Antimicrob Chemother"},{"key":"1291_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/jac\/dky027","volume":"73","author":"PM Hawkey","year":"2018","unstructured":"Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, Wilson APR. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party. J Antimicrob Chemother. 2018;73:2\u201378.","journal-title":"J Antimicrob Chemother"},{"key":"1291_CR35","doi-asserted-by":"publisher","first-page":"e00675-18","DOI":"10.1128\/AAC.00675-18","volume":"62","author":"F Robin","year":"2018","unstructured":"Robin F, Auzou M, Bonnet R, Lebreuilly R, Isnard C, Cattoir V, Gu\u00e9rin F. In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different \u03b2-lactam resistance phenotypes. Antimicrob Agents Chemother. 2018;62:e00675-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1291_CR36","unstructured":"Paterson D, Harris P. Pilot RCT of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Beta-lactamase Producing Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp. or Serratia Marcescens in Low-risk Patients. ClinicalTrials.gov Identifier NCT02437045. \n                    http:\/\/clinicaltrials.gov\n                    \n                  ."},{"key":"1291_CR37","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.ajic.2016.05.017","volume":"44","author":"KL Hammer","year":"2016","unstructured":"Hammer KL, Stoessel A, Justo JA, Bookstaver PB, Kohn J, Derrick CB, et al. Association between chronic hemodialysis and bloodstream infections caused by chromosomally mediated AmpC-producing Enterobacteriaceae. Am J Infect Control. 2016;44:1611\u20136.","journal-title":"Am J Infect Control"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-019-01291-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-019-01291-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-019-01291-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T19:14:14Z","timestamp":1583349254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-019-01291-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1007\/s15010-019-01291-9","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"24 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In the past 2 years, C.T. has been paid for lectures on behalf of Pfizer, Novartis, Merck, Angelini, Gilead, and Astellas. G.M.R. has received research grants from Angelini, Basilea, Menarini, Merck, Nordic Pharma, Pfizer, Rempex, Shionogi, VenatorX, Zambon; has received congress lecture fees from Angelini, Basilea, Merck, Pfizer, Zambon; has received consultancy fees from Angelini, Menarini, Merck, Nordic Pharma, Pfizer, Rempex, Shionogi, Zambon. The other authors have nothing to declare. All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency declarations"}}]}}